Total glucosides of paeony ameliorates TNBS‑induced colitis by modulating differentiation of Th17/Treg cells and the secretion of cytokines

Lin,Haihua; Zhang,Wenyou; Jiang,Xuepei; Chen,Renpin; Huang,Xielin; Huang,Zhiming

doi:10.3892/mmr.2017.7598

Total glucosides of paeony ameliorates TNBS‑induced colitis by modulating differentiation of Th17/Treg cells and the secretion of cytokines

Authors:
- Haihua Lin
- Wenyou Zhang
- Xuepei Jiang
- Renpin Chen
- Xielin Huang
- Zhiming Huang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Clinical Medicine, Renji College of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: September 25, 2017 https://doi.org/10.3892/mmr.2017.7598
Pages: 8265-8276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The imbalance between effector CD4+ T helper 17 (Th17) and regulatory CD4+ T cells (Treg) cells and their associated cytokines, have been associated with the pathogenesis of inflammatory bowel disease (IBD). Total glycosides of paeony (TGP) is an alternative immunomodulatory agent that is widely used for the treatment of autoimmune diseases. The present study aimed to evaluate the modulatory effect of TGP in a rat model of colitis induced by 2,4,6‑trinitrobenzene sulfonic acid (TNBS). TGP was administered intragastrically 24 h after the TNBS intrarectal instillation for 7 days. TGP treatment ameliorated the clinical status and reversed the histopathologic severity of acute TNBS colitis. Furthermore, TGP inhibited the levels of Th17‑associated cytokines interleukin (IL)‑17, IL‑6, tumor necrosis factor‑α, whereas the expression levels of Treg‑associated cytokines IL‑10, transforming growth factor‑β in the plasma, colon, spleen and mesenteric lymph nodes (MLN). Additionally, TGP reduced the percentage of Th17 cells; however, the proportion of Treg cells in the spleen and MLN was increased. The present study also observed a suppression of Th17‑associated transcription factor, termed retinoid‑related orphan receptor‑γt (ROR‑γt). However, expression of the Treg‑associated transcription factor forkhead boxp3 was increased in the TGP treatment group. Therefore, the present findings suggest that TGP has a regulatory role in modulating the balance of Th17 and Treg cells to ameliorate the TNBS‑induced colitis and support the strategy of using TGP to treat IBD.

View Figures

View References

1	Cătană CS, Neagoe I Berindan, Cozma V, Magdaş C, Tăbăran F and Dumitraşcu DL: Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 21:5823–5830. 2015. View Article : Google Scholar : PubMed/NCBI
2	Geremia A, Biancheri P, Allan P, Corazza GR and Di Sabatino A: Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 13:3–10. 2014. View Article : Google Scholar : PubMed/NCBI
3	Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M and Siegmund B: Histone deacetylases: Novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613–622. 2008. View Article : Google Scholar : PubMed/NCBI
4	Salim SY and Söderholm JD: Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 17:362–381. 2011. View Article : Google Scholar : PubMed/NCBI
5	Veltkamp C, Anstaett M, Wahl K, Möller S, Gangl S, Bachmann O, Hardtke-Wolenski M, Länger F, Stremmel W, Manns MP, et al: Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment. Gut. 60:1345–1353. 2011. View Article : Google Scholar : PubMed/NCBI
6	Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M and Duchmann R: Peripheral and intestinal regulatory CD4⁺ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 128:1868–1878. 2005. View Article : Google Scholar : PubMed/NCBI
7	Brand S: Crohn's disease: Th1, Th17 or both? The change of a paradigm: New immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 58:1152–1167. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kaser A, Zeissig S and Blumberg RS: Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010. View Article : Google Scholar : PubMed/NCBI
9	Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A and Barry S: Foxp3⁺ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 30:80–89. 2010. View Article : Google Scholar : PubMed/NCBI
10	Gaffen SL: An overview of IL-17 function and signaling. Cytokine. 43:402–407. 2008. View Article : Google Scholar : PubMed/NCBI
11	Dambacher J, Beigel F, Zitzmann K, De Toni EN, Göke B, Diepolder HM, Auernhammer CJ and Brand S: The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 58:1207–1217. 2009. View Article : Google Scholar : PubMed/NCBI
12	Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T and Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
13	Nielsen OH, Kirman I, Rüdiger N, Hendel J and Vainer B: Upregulation of interleukin-12 and −17 in active inflammatory bowel disease. Scand J Gastroenterol. 38:180–185. 2003. View Article : Google Scholar : PubMed/NCBI
14	Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM and Lipsky PE: TNF downmodulates the function of human CD4⁺CD25^hi T-regulatory cells. Blood. 108:253–261. 2006. View Article : Google Scholar : PubMed/NCBI
15	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
16	O'Garra A and Vieira P: Regulatory T cells and mechanisms of immune system control. Nat Med. 10:801–805. 2004. View Article : Google Scholar : PubMed/NCBI
17	Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H and Powrie F: Control of intestinal inflammation by regulatory T cells. Immunol Rev. 182:190–200. 2001. View Article : Google Scholar : PubMed/NCBI
18	Mottet C, Uhlig HH and Powrie F: Cutting edge: Cure of colitis by CD4⁺CD25⁺ regulatory T cells. J Immunol. 170:3939–3943. 2003. View Article : Google Scholar : PubMed/NCBI
19	Galvez J: Role of Th17 cells in the pathogenesis of Human IBD. ISRN Inflamm. 2014:9284612014. View Article : Google Scholar : PubMed/NCBI
20	Hansen R, Thomson JM, El-Omar EM and Hold GL: The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol. 45:266–276. 2010. View Article : Google Scholar : PubMed/NCBI
21	Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar : PubMed/NCBI
22	Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR and Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 441:231–234. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhu J and Paul WE: Heterogeneity and plasticity of T helper cells. Cell Res. 20:4–12. 2010. View Article : Google Scholar : PubMed/NCBI
24	Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wu CF: A review on the pharmacology of Paeonia lactiflora and its chemical components. Zhong Yao Tong Bao. 10:43–45. 1985.(In Chinese). PubMed/NCBI
26	Zhang LL, Wei W, Wang NP, Wang QT, Chen JY, Chen Y, Wu H and Hu XY: Paeoniflorin suppresses inflammatory mediator production and regulates G protein-coupled signaling in fibroblast-like synoviocytes of collagen induced arthritic rats. Inflamm Res. 57:388–395. 2008. View Article : Google Scholar : PubMed/NCBI
27	He DY and Dai SM: Anti-inflammatory and immunomodulatory effects of Paeonia lactiflora Pall., a traditional chinese herbal medicine. Front Pharmacol. 2:102011. View Article : Google Scholar : PubMed/NCBI
28	Lee B, Shin YW, Bae EA, Han SJ, Kim JS, Kang SS and Kim DH: Antiallergic effect of the root of Paeonia lactiflora and its constituents paeoniflorin and paeonol. Arch Pharm Res. 31:445–450. 2008. View Article : Google Scholar : PubMed/NCBI
29	Kim ID and Ha BJ: The effects of paeoniflorin on LPS-induced liver inflammatory reactions. Arch Pharm Res. 33:959–966. 2010. View Article : Google Scholar : PubMed/NCBI
30	Lin J, Xiao L, Ouyang G, Shen Y, Huo R, Zhou Z, Sun Y, Zhu X, Zhang J, Shen B and Li N: Total glucosides of paeony inhibits Th1/Th17 cells via decreasing dendritic cells activation in rheumatoid arthritis. Cell Immunol. 280:156–163. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zhu L, Wei W, Zheng YQ and Jia XY: Effects and mechanisms of total glucosides of paeony on joint damage in rat collagen-induced arthritis. Inflamm Res. 54:211–220. 2005. View Article : Google Scholar : PubMed/NCBI
32	Wu Y, Ren K, Liang C, Yuan L, Qi X, Dong J, Shen J and Lin S: Renoprotective effect of total glucosides of paeony (TGP) and its mechanism in experimental diabetes. J Pharmacol Sci. 109:78–87. 2009. View Article : Google Scholar : PubMed/NCBI
33	Huang Q, Ma X, Zhu DL, Chen L, Jiang Y, Zhou L, Cen L, Pi R and Chen X: Total glucosides of peony attenuates experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol. 284:67–73. 2015. View Article : Google Scholar : PubMed/NCBI
34	Zhao M, Liang GP, Tang MN, Luo SY, Zhang J, Cheng WJ, Chan TM and Lu QJ: Total glucosides of paeony induces regulatory CD4(+)CD25(+) T cells by increasing Foxp3 demethylation in lupus CD4(+) T cells. Clin Immunol. 143:180–187. 2012. View Article : Google Scholar : PubMed/NCBI
35	Cao W, Zhang W, Liu J, Wang Y, Peng X, Lu D, Qi R, Wang Y and Wang H: Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-α and IL-1β release and augmentation of IL-10 production. Int Immunopharmacol. 11:172–178. 2011. View Article : Google Scholar : PubMed/NCBI
36	Liu GL, Li YC and Shen YJ: Inhibitory effect of total glucosides of paeonia on the NF-κB/p65 protein expression in paws of RA rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26:1082–1084. 2010.(In Chinese). PubMed/NCBI
37	Zhang Y, Zhou R, Zhou F, Cheng H and Xia B: Total glucosides of peony attenuates 2,4,6-trinitrobenzene sulfonic acid/ethanol-induced colitis in rats through adjustment of TH1/TH2 cytokines polarization. Cell Biochem Biophys. 68:83–95. 2014. View Article : Google Scholar : PubMed/NCBI
38	Wirtz S, Neufert C, Weigmann B and Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2:541–546. 2007. View Article : Google Scholar : PubMed/NCBI
39	Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M and Li X: Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 15:341–352. 2009. View Article : Google Scholar : PubMed/NCBI
40	Zou Y, Li WY, Wan Z, Zhao B, He ZW, Wu ZG, Huang GL, Wang J, Li BB, Lu YJ, et al: Huangqin-Tang ameliorates TNBS-induced colitis by regulating effector and regulatory CD4(+) T cells. Biomed Res Int. 2015:1020212015. View Article : Google Scholar : PubMed/NCBI
41	Bell CJ, Gall DG and Wallace JL: Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol. 268:G622–G630. 1995.PubMed/NCBI
42	Scheiffele F and Fuss IJ: Induction of TNBS colitis in mice. Curr Protoc Immunol Chapter. 15:Unit 152002.
43	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
44	Himmel ME, Yao Y, Orban PC, Steiner TS and Levings MK: Regulatory T-cell therapy for inflammatory bowel disease: More questions than answers. Immunology. 136:115–122. 2012. View Article : Google Scholar : PubMed/NCBI
45	Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007. View Article : Google Scholar : PubMed/NCBI
46	Baumgart DC and Sandborn WJ: Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
47	Strober W, Fuss IJ and Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol. 20:495–549. 2002. View Article : Google Scholar : PubMed/NCBI
48	Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ and Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 8:967–974. 2007. View Article : Google Scholar : PubMed/NCBI
49	Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ and Littman DR: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17⁺ T helper cells. Cell. 126:1121–1133. 2006. View Article : Google Scholar : PubMed/NCBI
50	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol. 4:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
51	Tamboli CP: Current medical therapy for chronic inflammatory bowel diseases. Surg Clin North Am. 87:697–725. 2007. View Article : Google Scholar : PubMed/NCBI
52	Zhou J, Wu ZX, Yang JH, et al: Effect of total glucosides of Paeony on TNBS-in duced experimental Colitis in rats. Chin J Gastroenterol. 4:154–158. 2009.